Myriad Genetics
MYGN
MYGN
197 hedge funds and large institutions have $2.16B invested in Myriad Genetics in 2021 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 76 increasing their positions, 63 reducing their positions, and 37 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
197
Holders Change
-16
Holders Change %
-7.51%
% of All Funds
3.04%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
24
Increased
76
Reduced
63
Closed
37
Calls
$11M
Puts
$2.77M
Net Calls
+$8.21M
Net Calls Change
+$4.89M
Top Buyers
| 1 |
BlackRock
New York
|
+$31M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$30.2M |
| 3 |
Millennium Management
New York
|
+$15.8M |
| 4 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$13.9M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.21M |
Top Sellers
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$23.4M |
| 2 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$19.1M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$18.9M |
| 4 |
GCM
Glenview Capital Management
New York
|
-$15.3M |
| 5 |
Morgan Stanley
New York
|
-$11.2M |
